Replies to post #105269 on Biotech Values

[linhdtu]

Is it that Sandoz/Mnta do have a decent chance to win thier suit against Teva based on inequitable conduct ?

[exwannabe]

Re: "I’m surprised no one here has commented on a MNTA matter I posted about recently that could turn out to be more consequential to investors than the minutia of the Lovenox launch. Does anyone know what I’m referring to?"

I do not think you are posting about inequitable conduct, as somebody has commented on how that effects MNTA.

I will go with the valuation on the ENDP buyout of ?? deal.

[RockRat]

You're likely referring to the early November FDA hearings about biosimilar/FoB regulations, with input from pharma execs.

A draft document is apparently out, but the FDA won't comment on it:

http://thehill.com/blogs/healthwatch/prescription-drug-policy/119735-fda-calls-for-hearing-on-biosimilars-legislation

I haven't read the whole thing yet, but it looks as though anyone can submit an electronic comment.

Regards, RockRat